Literature DB >> 1759841

Ofloxacin penetration into tuberculous pleural effusion.

W W Yew1, J Lee, C Y Chan, S W Cheung, P C Wong, S Y Kwan.   

Abstract

After 3 days of treatment with ofloxacin (300 mg given orally once daily), the drug levels in serum and pleural fluid 2 and 4 h after drug administration in patients with tuberculous pleural effusion were assessed by a rapid high-performance liquid chromatography assay. The levels in serum (mean +/- standard error of the mean [SEM]) were 4.70 +/- 0.14 and 4.63 +/- 0.09 mg/liter 2 and 4 h after administration, respectively, and the levels in pleural fluid (mean +/- SEM) were 3.82 +/- 0.09 and 4.21 +/- 0.08 mg/liter, respectively. The pleural fluid-to-serum ofloxacin ratio at 2 h was 0.82 +/- 0.02 (mean +/- SEM), and the ratio at 4 h was 0.92 +/- 0.02 (mean +/- SEM). This study demonstrated very good penetration of ofloxacin into pleural fluid in tuberculous pleuritis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1759841      PMCID: PMC245347          DOI: 10.1128/AAC.35.10.2159

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Current concepts of tuberculous pleurisy with effusion as derived from pleural biopsy studies.

Authors:  W B ABRAMS; M J SMALL
Journal:  Dis Chest       Date:  1960-07

Review 2.  Tuberculous pleurisy.

Authors:  H W Berger; E Mejia
Journal:  Chest       Date:  1973-01       Impact factor: 9.410

3.  Diagnosis of tuberculous pleurisy by culture of pleural biopsy specimen.

Authors:  H Levine; W Metzger; D Lacera; L Kay
Journal:  Arch Intern Med       Date:  1970-08

4.  In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis.

Authors:  W W Yew; S Y Kwan; W K Ma; M A Khin; P Y Chau
Journal:  J Antimicrob Chemother       Date:  1990-08       Impact factor: 5.790

5.  Penetration of ciprofloxacin into human pleural fluid.

Authors:  F Jacobs; M Marchal; P de Francquen; J P Kains; D Gangji; J P Thys
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

6.  The penetration of ofloxacin into lung tissue.

Authors:  W J Wijnands; T B Vree; A M Baars; J C Hafkenscheid; B E Kohler; C L van Herwaarden
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

7.  Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis.

Authors:  M Tsukamura; E Nakamura; S Yoshii; H Amano
Journal:  Am Rev Respir Dis       Date:  1985-03

Review 8.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

9.  Diffusion of ofloxacin into human lung tissue.

Authors:  L Couraud; J B Fourtillan; M C Saux; A Bryskier; M Vincent du Laurier
Journal:  Drugs       Date:  1987       Impact factor: 9.546

10.  Rapid HPLC assay of fluoroquinolones in clinical specimens.

Authors:  C Y Chan; A W Lam; G L French
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

View more
  3 in total

1.  Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers.

Authors:  S C Flor; M C Rogge; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

2.  Penetration of amphotericin B lipid formulations into pleural effusion.

Authors:  Stefan Weiler; Rosa Bellmann-Weiler; Michael Joannidis; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2007-09-04       Impact factor: 5.191

Review 3.  Role of Antimicrobial Peptides in Treatment and Prevention of Mycobacterium Tuberculosis: A Review.

Authors:  Kanchan Mehta; Prince Sharma; Shama Mujawar; Ashish Vyas
Journal:  Int J Pept Res Ther       Date:  2022-07-22       Impact factor: 2.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.